A Prospective Diagnostic Accuracy Study of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, Multidetector Row Computed Tomography, and Magnetic Resonance Imaging in Primary Diagnosis and Staging of Pancreatic Cancer
Abstract
In Brief Objective: To prospectively compare the accuracy of combined positron emission tomography/computed tomography using 18F-fluorodeoxyglucose (FDG-PET/CT), multidetector row computed tomography (MDCT), and magnetic resonance imaging (MRI) in the evaluation of patients with suspected pancreatic malignancy. Summary Background Data: FDG-PET/CT imaging is increasingly used for staging of pancreatic cancer. Preliminary data suggest a significant influence of FDG-PET/CT on treatment planning, although its role is still evolving. Methods: Thirty-eight consecutive patients with suspicion of pancreatic malignancy were enrolled. Patients underwent a protocol including FDG-PET/CT, MDCT, and MRI combined with magnetic resonance cholangiopancreatography, all of which were blindly evaluated. The findings were confirmed macroscopically at operation and/or by histopathologic analysis (n = 29) or follow-up (n = 9). Results of TNM classification of different imaging methods were compared with clinical TNM classification. Results: Pancreatic adenocarcinoma was diagnosed in 17 patients, neuroendocrine tumor in 3, mass-forming pancreatitis in 4, cystic lesion in 6, and fibrosis in 2. Six patients had a finding of a normal pancreas. The diagnostic accuracy of FDG-PET/CT for pancreatic malignancy was 89%, compared with 76% and 79% for MDCT and MRI, respectively. In the differential diagnosis of suspected malignant biliary stricture at endoscopic retrograde cholangiopancreaticography (n = 21), FDG-PET/CT had a positive predictive value of 92%. In 17 patients with advanced pancreatic adenocarcinoma, FDG-PET/CT had a sensitivity of 30% for N- and 88% for M-staging. Both MDCT and MRI had sensitivities of 30% for N- and 38% for M-staging. Furthermore, the clinical management of 10 patients (26%) was altered after FDG-PET/CT. Conclusion: FDG-PET/CT was more sensitive than conventional imaging in the diagnosis of both primary pancreatic adenocarcinoma and associated distant metastases. In contrast, the sensitivity of FDG-PET/CT was poor in detecting local lymph node metastasis, which would have been important for an assessment of resectability. We recommend the use of FDG-PET/CT in the evaluation of diagnostically challenging cases, especially in patients with biliary strictures without evidence of malignancy in conventional imaging. The aim of the study was to prospectively compare 18F-fluorodeoxyglucose positron emission tomography or computed tomography, multidetector row computed tomography, and magnetic resonance imaging in the diagnosis of pancreatic cancer. In group of 38 patients, 18F-fluorodeoxyglucose positron emission tomography or computed tomography was more sensitive than conventional imaging in the diagnosis of both primary pancreatic adenocarcinoma and associated distant metastases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The sensitivity and specificity of CT for pancreatic cancer diagnosis is 76-92% and 67%, respectively.
“The sensitivity and specificity of CT for pancreatic cancer diagnosis is 76–92% (23-25) and 67% (23), respectively.”
From Suspicious findings observed retrospectively on CT imaging performed before the diagnosis of pancreatic cancer (2023) · cites this paper as [23]
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Early Detection of Pancreatic Cancer: Opportunities and Challenges
Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841 · see citing works
Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer
Tummers, W. S., Willmann, J. K., Bonsing, B. A., Vahrmeijer, A. L., Gambhir, S. S., & Swijnenburg, R.-J. (2018) · Pancreas · doi:10.1097/mpa.0000000000001075 · Cited by 50 · see citing works
Surveillance for neoplasia in the pancreas
Overbeek, K. A., Cahen, D. L., Canto, M. I., & Bruno, M. J. (2016) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2016.10.013 · Cited by 28 · see citing works
Park, B. K., Koh, H. D., Won, S. Y., Cho, Y. S., Seo, J. H., An, C., & Park, S. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-863 · Cited by 10 · see citing works
“The sensitivity and specificity of CT for pancreatic cancer diagnosis is 76–92% (23-25) and 67% (23), respectively.”
- Authors
- Kauhanen, S. P., Komar, G., Seppänen, M. P., Dean, K. I., Minn, H. R., Kajander, S. A., Rinta-Kiikka, I., Alanen, K., Borra, R. J., Puolakkainen, P. A., Nuutila, P., & Ovaska, J. T.
- Affiliations
- University of Turku (FI)
- Turku University Hospital (FI)
- Tampere University Hospital (FI)
- Corresponding author
- Kauhanen, Saila P.
- Komar, Gaber
- Seppänen, Marko P.
- Minn, Heikki R.
- Kajander, Sami A.
- Borra, Ronald J.
- Nuutila, Pirjo
- ORCID
- Venue
- Annals of Surgery
- Published
- 2009-12
- Volume
- 250
- Issue
- 6
- Pages
- 957-963
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W1972313686
- Cited by
- 317
- References
- 1
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 15 · 2023: 14 · 2022: 15 · 2021: 22 · 2020: 26 · 2019: 18 · 2018: 21 · 2017: 31 · 2016: 23 · 2015: 32 · 2014: 19 · 2013: 21 · 2012: 23
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Surgery (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Oncology › Peptidase Inhibition and Analysis
- Keywords
- pancreatic cancer, FDG PET/CT, pancreatic ductal adenocarcinoma, diagnostic accuracy, tumor staging, multidetector computed tomography, magnetic resonance imaging, magnetic resonance cholangiopancreatography, pancreatic neuroendocrine tumors, mass-forming pancreatitis, pancreatic cysts, distant metastasis, TNM classification, treatment planning
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Prospective Studies, Tomography, X-Ray Computed, Reproducibility of Results, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography, Cholangiopancreatography, Magnetic Resonance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review